Viracta Therapeutics ( NASDAQ:VIRX – Get Rating ) had its price target decreased by HC Wainwright from $35.00 to $33.00 in a research report released on Wednesday, The Fly reports. HC Wainwright also issued estimates for Viracta Therapeutics' Q2 2023 earnings at ($0.32) EPS, Q3 2023 earnings at ($0.33) EPS, Q4 2023 earnings at ($0.33) EPS and FY2023 earnings at ($1.30) EPS. VIRX has been the topic of several other research reports. Royal Bank of Canada reaffirmed an outperform rating and set a $8.

https://www.dailypolitical.com/2023/05/14/viracta-therapeutics-nasdaqvirx-pt-lowered-to-33-00.html

#dailypolitical